esmocard 2500 mg inj. sol. (pwdr., conc.) i.v. vial
orpha-devel handels und vertriebs gmbh - esmolol hydrochloride 2500 mg - powder for concentrate for solution for infusion - 2500 mg - esmolol hydrochloride 2500 mg - esmolol
feiba nf
takeda new zealand limited - factor viii inhibitor bypassing fraction 2500 u; ; - powder for injection with diluent - 2500 u - active: factor viii inhibitor bypassing fraction 2500 u excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.
prosaro
bayer new zealand limited - prothioconazole; tebuconazole - emulsifiable concentrate - prothioconazole 125 g/litre; tebuconazole 125 g/litre - fungicide - fungicide
dovenix 250 mg/ml inj. sol. s.c. vial
boehringer ingelheim animal health belgium (decommissioned) sa-nv - nitroxinil 250 mg/ml - solution for injection - 250 mg/ml - nitroxinil 250 mg/ml - nitroxinil - cattle; sheep
cefuroxime 250mg
douglas pharmaceuticals limited - cefuroxime sodium 256mg equivalent to 250 mg cefuroxime anhydrous; - powder for injection - 250 mg - active: cefuroxime sodium 256mg equivalent to 250 mg cefuroxime anhydrous
ibiamox
douglas pharmaceuticals limited - amoxicillin sodium 250mg; - powder for injection - 250 mg - active: amoxicillin sodium 250mg - amoxicillin should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. amoxicillin is indicated for the treatment of infections at the following sites, when caused by sensitive organism: · upper respiratory tract including ear, nose and throat infections, e.g. tonsillitis, sinusitis, otitis media. · lower respiratory tract, e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia. · gastrointestinal tract, e.g. typhoid fever. · genito-urinary tract, e.g. cystitis, urethritis, pyelonephritis, bacteriuria in pregnancy, gonorrhoea, septic abortion, puerperal sepsis. · other infections including borreliosis (borrelia burgdorferi) (lyme disease). · prophylaxis of endocarditis: amoxicillin may be used for the prevention of bacteraemia associated with the development of endocarditis. · skin and soft tissue infecitons (sstis). susceptibility to amoxicillin with vary with geography and time and local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary.
vitamin c 250mg - plain
healtheries of new zealand limited - ascorbic acid 250mg (approx. 4% overage added) - tablet - 250 mg - active: ascorbic acid 250mg (approx. 4% overage added) excipient: magnesium stearate microcrystalline cellulose sucrose
bivalirudin accord healthcare 250 mg inj./inf. sol. (pwdr., conc.) i.v. vial
accord healthcare b.v. - bivalirudin 250 mg - powder for concentrate for solution for injection/infusion - 250 mg - bivalirudin 250 mg - bivalirudin
floxapen 250 mg inj./inf. sol. (pwdr.) i.v./i.m. vial
eugia pharma (malta) ltd. - flucloxacillin sodium monohydrate - eq. flucloxacillin 250 mg - powder for solution for injection/infusion - 250 mg - flucloxacillin 250 mg - flucloxacillin
lassardeeg purna 250 mg/g - 10 mg/g ointm. jar
purna pharmaceuticals sa-nv - salicylic acid 10 mg/g; zinc oxide 250 mg/g - ointment - 250 mg/g - 250 mg/g - 10 mg/g - salicylic acid 10 mg/g; starch 250 mg/g; zinc oxide 250 mg/g - zinc products